348 related articles for article (PubMed ID: 31856792)
1. Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Luo Q; Jin Q; Zhao Z; Zhao Q; Yu X; Yan L; Zhang Y; Xiong C; Liu Z
BMC Pulm Med; 2019 Dec; 19(1):257. PubMed ID: 31856792
[TBL] [Abstract][Full Text] [Related]
2. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Ogawa A; Miyaji K; Matsubara H
Respir Med; 2017 Oct; 131():215-219. PubMed ID: 28947033
[TBL] [Abstract][Full Text] [Related]
4. Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.
Zhang L; Wang Y; Zhang R
Medicine (Baltimore); 2021 Oct; 100(41):e27334. PubMed ID: 34731104
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.
Montani D; Achouh L; Dorfmüller P; Le Pavec J; Sztrymf B; Tchérakian C; Rabiller A; Haque R; Sitbon O; Jaïs X; Dartevelle P; Maître S; Capron F; Musset D; Simonneau G; Humbert M
Medicine (Baltimore); 2008 Jul; 87(4):220-233. PubMed ID: 18626305
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Ogawa A; Miyaji K; Yamadori I; Shinno Y; Miura A; Kusano KF; Ito H; Date H; Matsubara H
Circ J; 2012; 76(7):1729-36. PubMed ID: 22481098
[TBL] [Abstract][Full Text] [Related]
7. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
Montani D; Girerd B; Jaïs X; Levy M; Amar D; Savale L; Dorfmüller P; Seferian A; Lau EM; Eyries M; Le Pavec J; Parent F; Bonnet D; Soubrier F; Fadel E; Sitbon O; Simonneau G; Humbert M
Lancet Respir Med; 2017 Feb; 5(2):125-134. PubMed ID: 28087362
[TBL] [Abstract][Full Text] [Related]
9. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease.
Montani D; Jaïs X; Price LC; Achouh L; Degano B; Mercier O; Mussot S; Fadel E; Dartevelle P; Sitbon O; Simonneau G; Humbert M
Eur Respir J; 2009 Dec; 34(6):1348-56. PubMed ID: 19541723
[TBL] [Abstract][Full Text] [Related]
10. Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.
Ogawa A; Takahashi Y; Matsubara H
J Cardiol; 2018 Sep; 72(3):255-260. PubMed ID: 29548663
[TBL] [Abstract][Full Text] [Related]
11. Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review.
Ogawa A; Sakao S; Tanabe N; Matsubara H; Tatsumi K
Respir Investig; 2019 Mar; 57(2):183-190. PubMed ID: 30473253
[TBL] [Abstract][Full Text] [Related]
12. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
[TBL] [Abstract][Full Text] [Related]
14. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.
Palmer SM; Robinson LJ; Wang A; Gossage JR; Bashore T; Tapson VF
Chest; 1998 Jan; 113(1):237-40. PubMed ID: 9440597
[TBL] [Abstract][Full Text] [Related]
15. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
[TBL] [Abstract][Full Text] [Related]
16. Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Sakao S; Tanabe N; Tatsumi K
J Am Heart Assoc; 2019 Aug; 8(16):e013310. PubMed ID: 31423872
[No Abstract] [Full Text] [Related]
17. [Clinical characteristics and survival of patients with pulmonary veno-occlusive disease].
Jiang X; Chen FD; He J; Jiang R; Di RM; Zhao QH; Jing ZC
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):896-900. PubMed ID: 22321271
[TBL] [Abstract][Full Text] [Related]
18. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
[TBL] [Abstract][Full Text] [Related]
19. [Pulmonary arterial hypertension from the risk assessment to combined treatment].
Santos-Martínez LE; Moreno-Ruiz LA; Cabrera-Ramírez C; Mendoza-Pérez BC; Galván-Oseguera H; Magaña-Serrano JA; Lupercio-Mora K; Saturno-Chiu G
Rev Med Inst Mex Seguro Soc; 2019 Sep; 57(5):314-323. PubMed ID: 32568487
[TBL] [Abstract][Full Text] [Related]
20. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
